Lewes, DE -- (SBWIRE) -- 03/23/2015 -- Deal Values in Pharmaceutical & Healthcare Industry Increased in Q4 2014

"Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q4 2014. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

Publisher derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.

Deal Values Of M&A's Increased In Q4 2014

Merger and acquisition (M&A) deals, including asset purchases, recorded decrease in the number of deals and increase in deal values in Q4 2014 with 204 deals worth $108.4 billion, compared to 360 deals worth $35.7 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals decreased and their values increased in Q4 2014, compared to 267 deals worth $55.2 billion in Q3 2014.

The central nervous system therapeutics markets recorded the highest number of deals in Q4 Q4 2014 and stood at the top in deal activity. The market recorded 27 deals worth $86.1 billion in Q4 2014.

Partnership Deals Increased In Q4 2014

Partnership deals reported a decrease in the number of deals and an increase in deal values in Q4 2014 with 184 deals worth $8.3 billion, as compared to 208 deals worth $7 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals and deal values increased in Q4 2014, when compared to 140 deals worth $4.3 billion in Q3 2014.

Pharmaceutical and healthcare companies entered into 76 partnerships for Marketed stage products, which accounted for 31% of the deals from Q4 2013 to Q4 2014. Products in Discovery phase stood second with 51 deals, which accounted for 21% of the deals.

Licensing Deals Repoted An Increase In Number In Q4 2014

Licensing agreements recorded an increase in the number of deals and deal values in Q4 2014 with 163 deals worth $11.6 billion, as compared to 155 deals worth $6.4 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals and deal values increased in Q4 2014, when compared with 124 deals worth $7.5 billion in Q3 2014.

Licensing agreements recorded increase in the receipt of upfront payments and milestone payments in Q4 2014. The segment reported $729.2m and $6.6 billion as upfront and milestone payments in Q4 2014, compared to $296.3m and $5 billion, respectively, in Q4 2013. On a quarter-on-quarter basis, the receipt of upfront payments and milestone payments increased in Q4 2014, compared to $295.9m and $4.4 billion, respectively, in Q3 2014.

In licensing by phase, products in Phase II recorded 95 deals, which accounted for 26% of the total deals between Q4 2013 and Q4 2014. In second place, products in Marketed accounted for 23% of the deals.

Venture Capital Investments Remained Same In Q4 2014

The pharmaceutical and healthcare industry recorded a decrease in the number of venture capital (VC) deals and their values with 167 deals worth $2.1 billion in Q4 2014, as compared to 298 deals worth $2.8 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals decreased and deal values increased marginally in Q4 2014, when compared to 233 deals worth $2 billion in Q3 2014. Deals in start-up stage constituted 54% of the total deals in Q4 2014. In second place, growth/expansion stage financing recorded 54 deals, accounting for 32% of the total deals.

Orbimed Advisors, LLC topped the list of venture financing firms by participating in 20 transactions worth $695.3m in the last five quarters (Q4 2013 - Q4 2014).

North America Reported An Increase In Values In Q4 2014

North America recorded decrease in the number of deals and increase in deal values in Q4 2014. The region registered 645 deals worth $158.8 billion in Q4 2014, compared to 895 deals worth $66.7 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2014, when compared to 689 deals worth $64.4 billion in Q3 2014.

Europe recorded a decrease in the number of deals and an increase in deal values in Q4 2014 with 339 deals worth $43.9 billion, as compared to 350 deals worth $19 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals increased and deal values decreased in Q4 2014, when compared to 257 deals worth $47.8 billion in Q3 2014.

Asia Pacific recorded a decrease in the number of deals and increase in deal values in Q4 2014. The region reported 190 deals worth $16.1 billion in Q4 2014, as compared to 278 deals worth $12 billion in Q4 2013. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q4 2014, when compared to 213 deals worth $18.8 billion in Q3 2014.

For further information on this report, please visit- http://www.marketresearchreports.com/globaldata/partnerships-licensing-investments-and-ma-deals-and-trends-pharmaceuticals-q4-2014

Find all Finance and Investment (Pharma and Healthcare) Reports at:
http://www.marketresearchreports.com/finance-investment-pharma-healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at:
http://www.marketresearchreports.com/subscribe-to-newsletter